MET and cancer: This analysis revealed that AP21967 treatment upregulated the expression of genes in several downstream cancer progression pathways in MDA-MB-231-iDimerize-c-Met-β1 cells, including increased HIF-1 signaling pathway and a variety of metabolic pathways (Figure 1D).